◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276) Revenue 2022–2025

Name: Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276) revenue history 2022-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Jiangsu Hengrui Pharmaceuticals Co.,Ltd annual revenue for fiscal 2025 was CNY 31.6 billion, an increase of 13.0% from CNY 28.0 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

1276 Annual Revenue

Revenue (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 31.6B	CNY 28.0B	CNY 22.8B	CNY 21.3B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1276 Quarterly Revenue

Revenue (quarterly)	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	CNY 8.1B	CNY 8.4B	CNY 8.6B	CNY 7.2B	CNY 7.8B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4507 Revenue — Shionogi & Co., Ltd.
4523 Revenue — Eisai Co., Ltd.
4151 Revenue — Kyowa Kirin Co., Ltd.
4506 Revenue — Sumitomo Pharma Co., Ltd.
4540 Revenue — Tsumura & Co.
4516 Revenue — Nippon Shinyaku Co., Ltd.

More 1276 metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All 1276 financial statements → Interactive 1276 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.